SRT2104


Selective small-molecule allosteric activator of NAD-dependent protein deacetylase sirtuin 1 (SIRT1)

A second-generation imidazothiazole-scaffold sirtuin 1 activator developed by Sirtris Pharmaceuticals and advanced through multiple Phase 2 clinical programs by GlaxoSmithKline, distinguished from first-generation sirtuin-activating compounds by high target selectivity and favorable oral pharmacokinetics.

Abstract

SRT2104 (GSK2245840) is a synthetic, orally bioavailable, small-molecule allosteric activator of the NAD-dependent protein deacetylase sirtuin 1 (SIRT1, silent mating type information regulation 2 homolog 1), developed at Sirtris Pharmaceuticals and subsequently advanced into clinical trials by GlaxoSmithKline following the 2008 acquisition of Sirtris for approximately 720 million United States dollars. The compound is a second-generation sirtuin-activating compound (STAC) built on an optimized imidazo[2,1-b]thiazole scaffold and is reported to activate SIRT1 deacetylase activity approximately 1000-fold more potently than the natural polyphenol resveratrol in fluorophore-tagged peptide substrate assays, with minimal activity against a panel of more than 180 non-SIRT1 targets including kinases, G-protein-coupled receptors, nuclear receptors, ion channels, enzymes, and transporters [1, 2]. The allosteric mechanism involves binding to the N-terminal domain of SIRT1, lowering the Michaelis constant (Km) for the acetylated protein substrate without competing with either the NAD cofactor or the substrate acetyl-lysine site [3]. Downstream consequences of SIRT1 activation by SRT2104 include deacetylation and functional modulation of the transcription factor p53, the RelA/p65 subunit of nuclear factor kappa B (NF-kB), forkhead box protein O3 (FOXO3), peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1alpha), and signal transducer and activator of transcription 3 (STAT3), producing composite anti-inflammatory, metabolic, and cytoprotective effects that have been characterized across a broad range of preclinical disease models [4, 5].

The variable and non-dose-proportional pharmacokinetic profile has been identified as a principal limitation of the compound for clinical development in its current oral formulation. SRT2104 is poorly soluble in water and is formulated as a lipid-based oral capsule to improve bioavailability.

Clinical evaluation has spanned at least seven registered clinical trials across multiple indications. A separate cardiometabolic study in type 2 diabetic subjects reported trends toward improved endothelial function and arterial stiffness [9]. In a human endotoxemia model, SRT2104 pretreatment significantly reduced lipopolysaccharide-induced cytokine release (interleukin-6, interleukin-8) and coagulation activation, representing the first human demonstration of anti-inflammatory and anticoagulant activity consistent with pharmacological SIRT1 activation [12].

Preclinical pharmacology is extensive. The Mercken et al. (2014) study at the National Institute on Aging demonstrated that SRT2104 extends both mean and maximum lifespan of male mice fed a standard diet by 9.7 percent and 4.9 percent respectively, with preserved bone mineral density, muscle mass, motor coordination, and insulin sensitivity [13]. The Jiang et al. (2014) study demonstrated blood-brain barrier penetration, attenuation of brain atrophy, improvement of motor function, and extension of median lifespan by approximately 16 percent in N171-82Q Huntington disease model mice [14]. Additional preclinical evidence spans emphysema, sepsis, neonatal white matter injury, microglia polarization, dendritic outgrowth, and auditory cell senescence. GlaxoSmithKline discontinued active clinical development of SRT2104 following the 2013 closure of the Sirtris unit, though the compound remains widely used as a reference SIRT1 activator in academic and preclinical research. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.


Browse all monographs

Previous monograph
Next monograph